Powerful Anti-Estrogen Pharmaceutical Grade Anastrozole / Arimidex Raw Powder
Anastrozole is also called Arimidex, it can be referred to as an aromatase inhibitor which helps
prevent estrogen production in females. Research has shown that the estrogen hormone is
responsible for the creation of breast cancer tumors in women. Arimidex is the drug administered
to intercept the enzyme aromatase, which is a substance that assists the body tissues in
producing estrogen. Arimidex is a popular drug in the battle against breast cancer. It is by and
large, a hormonal treatment which can prevent the recurrence of breast cancer.
Arimidex is known to have diminished estrogen way too much in some patients. This is why blood
tests or salivary tests are recommended after a week of usage to determine whether the dosage
Arimidex tends to work quite differently than the traditional anti-estrogens. Anti-estrogens like
Clomid or Nolvadex tend to intercept estrogen receptors in certain tissues while activating them
in others. Meanwhile, Arimidex directly intercepts the enzyme aromatase. When a patient has
been recommended the use of Arimidex, Clomid use along with is unnecessary. Doing so may
have some benefits.
Arimidex is generally used for all stages and forms of breast cancer which are classified to be
estrogen receptor positive. In case the patient has estrogen receptor negative or triple negative
cancer, the usage of Arimidex is unlikely to help.
Lab Test Result:
White crystalline powder
Total Unspecified Impurity
Individual unspecified impurlty
Related compound B
Related compound C
Related compound D
Related compound E
Limit of cyclohexane
Limit of ethylacetate
Residue on ignition
It complies to USP32 Standard
An aromatase inhibitor. Used as an antineoplastic raw materials.
Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase
enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast
cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse
after adjuvant therapy after menopause for women with advanced breast cancer.
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when
one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not
have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen
blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex,
and for this reason blood tests, or less preferably salivary tests, should be taken after the first
week of use to determine if the dosing is correct.
Dosages of arimidex will vary from person to person. This is why blood work is essential to
finding the perfect balance. One should start out at half a mg every other day and adjust as
needed for the cycle. Some AAS users will not use an AI at first but they will have it on hand just in
case. This isn't always a good idea, as once you start noticing gyno or excessive water weight it
could be too late to reverse. Since AAS will continue building in the body and aromatize, taking
arimidex at this point would be like trying to stop a car already in motion.
General dosage for men: 0.5 mg per day or every other day
Anastrozole VS Letrozole
Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in
postmenopausal women suffering from an estrogen receptor-positive disease. The currently
established group of anti-aromatase compounds comprises two reversible aromatase inhibitors
(anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator
exemestane. Although exemestane is the only widely used aromatase inactivator at this stage,
physicians very often have to choose between either anastrozole or letrozole in general practice.
These third-generation aromatase inhibitors Letrozole and Anastrozole, have recently
demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer
improving disease-free survival. However, although anastrozole and letrozole belong to the same
pharmacological class of agents (triazoles), an increasing body of evidence suggests that these
aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical
and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the
differences between the non-steroidal aromatase inhibitors allowing physicians to choose
between these compounds based on scientific evidence. Although we are waiting for the
important results of a still ongoing head-to-head comparison in patients with early breast cancer
at high risk for relapse, clinicians have to make their choices today. On the basis of available
evidence summarised here and until FACE-data become available, letrozole seems to be the
best choice for the majority of breast cancer patients whenever a non-steroidal aromatase
inhibitor has to be chosen in a clinical setting.
Tamoxifen Citrate (Nolvadex)
Clomifene Citrate (Clomid)
Toremifene Citrate (Fareston)